leisure time -WSS

leisure time

author：explore 2025-08-04 07:04:25 - browse：694

portrait of Jennifer Adair -- coverage from STAT — Jennifer Adair develops scalable, low cost gene therapies at the Fred Hutchinson Cancer Center and helped found the Global Gene Therapy Initiative. Fred Hutch News Service

BALTIMORE — Gene and cell therapies have transformed a handful of devastating disorders in the U.S. and Europe, with more treatments on the way. But those technologies have largely failed to reach most of the world.

These lags are ubiquitous in the current drug development system, where new therapies are approved in wealthy countries and then slowly leak out to low- and middle-income countries, many years later. In the case of gene therapy, that means countries most affected by a disease such as sickle cell may wait decades to access a curative therapy.

For the last few years, a handful of researchers in the U.S. and around the world have tried to find ways of ensuring global access to these technologies. In 2020, they formed the Global Gene Therapy Initiative, with an initial goal of setting up a gene therapy clinical trial for a hemoglobinopathy — such as a disease like sickle cell or beta thalassemia — or HIV in two different low- and middle-income countries by 2024.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Impact of Dobbs ruling felt at reproductive medicine meeting

explore

hotspot

WSS

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

WuXi Biologics execs register to lobby as Congress comes for the company

STAT Summit: Biotech founders on deal

The explosion of genetic testing requires a new approach

Boston hospital trains restaurant workers on naloxone for overdoses

The United States must get value

knowledge

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

How to save PrEP access — and even expand it

Impact of Dobbs ruling felt at reproductive medicine meeting

How one medical school became remarkably diverse

FDA struggles to regulate food additives, sometimes for decades

Peter Hotez and the public health issue of online harassment

Researchers explore possible ties between long Covid, menopause

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Hospital price transparency does save money, advocate argues

Cancer drug shortages should be causing more outrage

Ripples from Flovent's discontinuation is killing children with asthma

leisure time

Solve the antibiotic resistance crisis with preventive drugs

STAT Readout Newsletter: Today's biggest biotech updates

CVS is willing to dump 10% of its Medicare Advantage members

NIH confirmation hearing shows politicization of research

Ripples from Flovent's discontinuation is killing children with asthma

STAT reporters are Pulitzer Prize finalists for investigative reporting

hotspot

explore

hotspot

focus